0
0
Researchers at the Indian Institute of Technology (IIT) Madras have developed an innovative, affordable microfluidic device that rapidly determines bacterial resistance or susceptibility to antibiotics. This breakthrough technology, unveiled in 2025, promises to revolutionize antimicrobial susceptibility testing (AST), particularly in resource-limited settings, by delivering results within three hours—a significant advancement over traditional methods that take 48 to 72 hours.
Antimicrobial resistance (AMR) is a critical global health threat identified by the World Health Organization (WHO) as one of the top 10 threats to humanity. In 2019, approximately 4.95 million deaths worldwide were associated with bacterial AMR, disproportionately impacting low and middle-income countries with limited diagnostic infrastructure. Rapid, accurate AST is vital for guiding effective treatment and curbing misuse of antibiotics, a leading cause of resistance.
The new device, named ε-D, leverages electrochemical impedance spectroscopy integrated into a lab-on-chip format with screen-printed carbon electrodes embedded within a simple microfluidic chip. This contrasts sharply with existing expensive, complex AST platforms requiring costly metals and specialized technicians. The cost-effectiveness and ease-of-use of ε-D enable its deployment in smaller clinics and rural healthcare centers where advanced labs are unavailable.
As explained by S Pushpavanam, Y B G Varma Institute Chair Professor, Department of Chemical Engineering at IIT Madras, the device meets several WHO criteria for ideal diagnostics: affordability, speed, ease of operation, and reliability. It works by detecting electrical changes in a specially prepared nutrient solution that both supports bacterial growth and amplifies signal sensitivity. Growing bacteria alter this electrical property, which the device tracks to assess bacterial viability and antibiotic susceptibility.
The device’s capabilities were validated using two bacterial types: gram-negative Escherichia coli and gram-positive Bacillus subtilis. The team tested antibiotic responses using ampicillin, which kills bacteria, and tetracycline, which inhibits growth, confirming ε-D’s ability to detect both bactericidal and bacteriostatic effects effectively. The findings were published in Nature Scientific Reports, a peer-reviewed, open-access journal by Nature Portfolio, underscoring the rigorous scientific endorsement of this technology.
Experts not involved with the research appreciate its potential impact. Dr. Anjali Mehta, Infectious Diseases Specialist at a leading Indian hospital, commented, “Rapid AST tools such as ε-D could transform antibiotic stewardship in places where waiting days for culture results often leads to broad-spectrum antibiotic overuse, worsening resistance. A quick, reliable test is crucial to prescribing targeted therapy early, which can save lives and reduce AMR spread.”
The development addresses a pressing clinical need: traditional AST requires bacterial cultures grown over days, delaying targeted treatment initiation and often promoting empirical broad-spectrum antibiotic use. This delay not only jeopardizes patient outcomes, particularly in intensive care units but also contributes heavily to the global AMR crisis.
Ongoing clinical validation of ε-D is underway in collaboration with IIT Madras Institute Hospital, with commercialization plans through Kaappon Analytics India Private Limited. If widely adopted, this device could significantly enhance early diagnosis and personalized treatment of bacterial infections, especially in underserved regions, thus contributing to global health efforts against AMR.
However, limitations remain. As with any new technology, extensive multicenter clinical trials are essential to confirm its accuracy across diverse bacterial species and antibiotic classes. Additionally, adoption in clinical practice will require regulatory approvals and integration with healthcare workflows. Experts also caution that no single test can solve AMR without comprehensive stewardship programs and public health strategies.
For the general public, this innovative device signals hope for faster, more precise antibiotic treatment and better infection control. Health systems embracing such technologies could reduce unnecessary antibiotic exposure, preserving these vital drugs’ effectiveness for future generations.
Medical Disclaimer: This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.
References:
- https://health.economictimes.indiatimes.com/news/medical-devices/revolutionary-low-cost-device-from-iit-madras-transforms-antibiotic-resistance-testing/123500729?utm_source=top_story&utm_medium=homepage
